Stocks to Watch: NTPC, Ashok Leyland, JSW Steel, Paras Defence, Glenmark Pharma and more
Ashok Leyland: For the first time since 2011, Ashok Leyland announced a 1:1 bonus share issue. Alongside this, the company declared a dividend of ₹ 4.25 per share, resulting in a total payout of ₹ 1,248 crore. In the March quarter, the company reported a 38.4 percent year-on-year increase in net profit, which rose to ₹ 1,246 crore, aided significantly by a one-time tax credit of ₹ 173 crore. Revenue for the quarter grew 5.7 percent to ₹ 11,907 crore.
NTPC: NTPC, the largest power producer in the country, reported a 22.6 percent quarter-on-quarter increase in profit, which rose to ₹ 5,778 crore for the March quarter. Revenue during the quarter stood at ₹ 43,903.7 crore, reflecting a sequential growth of 6 percent.
JSW Steel: JSW Steel posted a 15.7 percent year-on-year rise in consolidated net profit to ₹ 1,503 crore for Q4FY25. The performance was supported by lower coking coal prices and better operating margins, which contributed to improved profitability.
Paras Defence and Space Technologies: Paras Defence and Space Technologies signed a strategic joint venture agreement with Israel-based Heven Drones. This partnership is set to enable the manufacturing of logistics and cargo drones in India. These drones are intended for both defence and civilian applications, marking a significant diversification in the company's operational scope.
Glenmark Pharmaceuticals: Glenmark Pharmaceuticals reported a stable performance for the March quarter. Revenue increased 6.3 percent year-on-year to ₹ 3,256 crore, while EBITDA rose by 11.2 percent. The company's adjusted net profit, excluding one-off items such as the generic Zetia litigation costs, stood at ₹ 347 crore. It also reported an EBITDA margin of 17.2 percent for the quarter.
Finolex Industries: Finolex Industries reported a 5 percent year-on-year decline in revenue, which came in at ₹ 1,171.8 crore. Net profit remained steady at ₹ 165 crore. However, the company faced margin pressure, with EBITDA falling 18 percent to ₹ 171.3 crore. EBITDA margin narrowed to 14.6 percent from 16.9 percent in the same quarter of the previous year.
Ashoka Buildcon: Ashoka Buildcon reported a strong 73.2 percent increase in net profit for the March quarter, which rose to ₹ 432.2 crore compared to ₹ 249.6 crore in the same period last year. Revenue for the quarter stood at ₹ 2,694.4 crore, which was 11.7 percent lower than ₹ 3,052 crore reported in the corresponding quarter of the previous year.
GE Vernova T&D India: GE Vernova T&D India reported a nearly three-fold increase in its net profit for the March quarter, which rose to ₹ 186.49 crore, driven by higher revenues. Total income for the quarter increased to ₹ 1,173.65 crore from ₹ 919.31 crore a year earlier. For the full financial year 2024-25, the company's net profit surged to ₹ 608.33 crore from ₹ 181.05 crore in the previous year, while total income rose to ₹ 4,354.89 crore from ₹ 3,190.46 crore.
Jaiprakash Associates: Lenders of Jaiprakash Associates approved a planned cash expenditure of ₹ 936.27 crore for the ongoing quarter. This amount includes ₹ 856.73 crore earmarked for routine operational expenses and ₹ 79.54 crore allocated for one-time costs, aimed at supporting the company's efforts to sustain operations.
Havells India: Havells India announced a ₹ 340 crore investment to expand cable manufacturing capacity at its Alwar facility. Post-expansion, the total annual cable production capacity at the plant is expected to reach 41.45 lakh kilometres. This capital expenditure is intended to cater to rising demand and enhance operational efficiency.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
34 minutes ago
- India Today
Come to office or leave: Google gets tough on work-from-office policy, starts offering voluntary exits
Google has taken a tougher approach towards remote work in the US, asking more employees to return to the office or opt for a voluntary exit package. The company has rolled out a new return-to-office (RTO) rule for teams working in key areas like Core, Marketing, Research, Knowledge & Information (K&I), and Communications. The K&I group includes employees involved in major products such as Google Search, commerce and part of this move, employees who have been working remotely but live within 50 miles of a Google office are being told to switch to a hybrid schedule. This means they must start coming to the office at least three days a week. While Google had already introduced a hybrid work policy in 2022, this new step expands its reach and makes the expectation go along with this, the company is offering a voluntary exit programme to certain US-based employees, according to the internal memo accessed by Business Insider. Those who choose to leave will get a severance package. A spokesperson for Google said this option is being provided to help the company focus on the work ahead, and it's already been tried in other teams with positive The memo, which is shared by a top Google executive, explained that the company is in the middle of an important change, especially with the rise of AI. To keep up with the pace of change, Google wants its teams to be more connected and collaborative, something it believes happens better with in-person voluntary exit is also being positioned as a chance for people who feel less connected to the company's goals to step away, while creating room for others to grow within the organisation. Google has clarified that this is not a round of layoffs, but a way to bring more focus and energy to important the announcement has raised some concerns. In the past, Google has followed similar exit offers with job cuts. In 2023, the company let go of around 12,000 employees globally, and this year too, it carried out smaller rounds of layoffs in teams like Treasury and Business it is not clear how many people will be impacted this time, the message is clear. Google wants more of its staff back in office, and those who are not willing may have the option to walk away.
Time of India
41 minutes ago
- Time of India
Challenging times for global trade; India will certainly cross USD 825 bn exports this fiscal: Piyush Goyal
The world trade is facing severe geo-political challenges, but India has consistently emerged as a winner in such times, and the country's exports of goods and services will certainly cross USD 825 billion in 2025-26, Commerce and Industry Minister Piyush Goyal said. Despite global economic uncertainties due to the Russia-Ukraine conflict, Israel-Hamas war and the Red Sea crisis, the country's overall exports touched an all-time high of USD 825 billion against USD 778 billion in 2023-24. As per estimates of certain multi-lateral bodies, there would be a contraction in global trade , Goyal said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Complete protection with iPru All-in-one Term Plan ICICI Pru Life Insurance Plan Get Quote Undo "The world is going through severe geo-political these are challenging times, but India has always emerged (as) a winner in challenging times and we did a record USD 825 billion exports in 2024-25. This year, we hope to do much better," he told PTI. When asked if last fiscal's figures will be crossed, he said: "We will certainly be able to cross that". Live Events Apex exporters' body FIEO has projected that the country's overall goods and services exports are expected to grow by over 21 per cent year-on-year to USD 1 trillion during 2025-26. Federation of Indian Export Organisations (FIEO) President S C Ralhan has said the healthy growth may come on account of international buyers seeking to diversify their sourcing in the wake of global economic uncertainties. In 2025-26, merchandise exports are expected to grow 12 per cent to USD 525-535 billion from USD 437 billion in 2024-25, while services exports are likely to rise by about 20 per cent year-on-year to USD 465-475 billion from USD 387 billion in the last fiscal, according to FIEO. The major sectors that are expected to show a significant jump in the shipments this fiscal include electronics, engineering, chemicals, textile and clothing, pharma and even the agriculture sector. Free trade agreements with countries such as the UAE, Australia and European Free Trade Association (EFTA) will also help boost exports in the coming months. The India-EFTA trade agreement is expected to come into force from October 1 this year. Goyal also said that FTAs signed during the Congress era were not good and have impacted domestic firms. They signed FTAs with countries like ASEAN , which are India's competitors; besides, they were not balanced, he said, adding that India opened more markets for those countries and "we did not get" good deals in return. On finished goods, he said, India removed the duties but import taxes on raw materials created inverted duty issues and that hurt "us a lot", he said. He added that now the Modi government is doing FTAs with developed countries/regions like Australia, the UK, EFTA, the EU, the UAE, Oman, Peru, and Chile. "Here we collaborate, there is no we are doing FTAs with well thought out strategies," Goyal said. India-EFTA signed the Trade and Economic Partnership Agreement (TEPA) on March 10, 2024. Under the pact, India has received an investment commitment of USD 100 billion in 15 years from the grouping while allowing several products such as Swiss watches, chocolates, and cut and polished diamonds at lower or zero duties. When asked if India would have to ease certain regulations to attract this investment, Goyal said it has been a commitment based on today's situation. "Prime Minister Narendra Modi is continuously focusing on ease of doing business, deregulation, reducing compliance burden, decriminalising the laws, making it attractive to do business in India," he said, adding that " I think this USD 100 billion will be exceeded and come faster".
Business Standard
an hour ago
- Business Standard
Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane
Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets. Xbrane Biopharma AB is a biotechnology company. It develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSources integrated drug substance and drug product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbranes global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbranes latest funding round, reinforcing the long-term alignment between the two companies. Neeraj Sharma, managing director & CEO of OneSource Specialty Pharma, said: The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbranes proven success in biosimilar development, combined with OneSources fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the worlds leading biotech companies. OneSource Specialty Pharma is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,200 professionals. On a consolidated basis, OneSource Specialty Pharma reported net profit of Rs 98.50 crore in Q4 March 2025 as against net loss of Rs 40.17 crore in Q4 March 2024. Net sales surged 482.38% YoY to Rs 425.95 crore in Q4 March 2025.
